Results 131 to 140 of about 2,193 (158)
Some of the next articles are maybe not open access.
Pretomanid for the treatment of pulmonary tuberculosis
Drugs of Today, 2020Discovering novel drugs active against Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), is currently one of the most unmet medical needs. In this context, pretomanid (PA-824), a novel nitroimidazole prodrug that targets both replicating and nonreplicating cells, is being developed by TB Alliance under license from Novartis ...
R, Thakare, A, Dasgupta, S, Chopra
openaire +2 more sources
Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids [PDF]
Bioorganic and Medicinal Chemistry Letters, 2016 Pretomanid (PA-824) is an important nitroimidazole antitubercular agent in late stage clinical trials. However, pretomanid is limited by poor solubility and high protein binding, which presents opportunities for improvement in its physiochemical properties.
Rakesh +2 more
exaly +3 more sources
In Vitro Activity of Pretomanid against Nontuberculous Mycobacteria
Antimicrobial Agents and Chemotherapy, 2022The prevalence and incidence of nontuberculous mycobacterium (NTM) infections are increasing globally (1).….
Huiwen Zheng +8 more
openaire +2 more sources
Drugs, 2019
Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimens, has been developed by the Global Alliance for TB Drug Development (TB Alliance) under license from Novartis, for the treatment for ...
openaire +2 more sources
Pretomanid, an oral nitroimidazooxazine antimycobacterial agent administered as part of the BPaL (bedaquiline, pretomanid and linezolid) and BPaMZ (bedaquiline, pretomanid, moxifloxacin and pyrazinamide) regimens, has been developed by the Global Alliance for TB Drug Development (TB Alliance) under license from Novartis, for the treatment for ...
openaire +2 more sources
Pretomanid: A novel therapeutic paradigm for treatment of drug resistant tuberculosis
Indian Journal of Tuberculosis, 2021Tuberculosis is currently an anticipated driver of pandemic diseases. It remains an imminent issue accounting for about 1.4 million deaths annually across the world. Since the evolution of human entity drug susceptible tuberculosis was managed through potent first line therapies.
Uzma Parveen +5 more
openaire +2 more sources
US FDA reviewing pretomanid for tuberculosis
C&EN Global Enterprise, 2019The US Food and Drug Administration is evaluating a new drug application for pretomanid, a new tuberculosis drug candidate.
exaly +2 more sources
American Journal of Respiratory and Critical Care Medicine, 2015
Abstract Rationale New regimens to shorten tuberculosis treatment and manage patients with drug-resistant tuberculosis who are infected with HIV are urgently needed. Experimental and clinical evidence suggests that the new drugs bedaquiline (B) and pretomanid (Pa), combined with an existing ...
Andreas H, Diacon +11 more
openaire +2 more sources
Abstract Rationale New regimens to shorten tuberculosis treatment and manage patients with drug-resistant tuberculosis who are infected with HIV are urgently needed. Experimental and clinical evidence suggests that the new drugs bedaquiline (B) and pretomanid (Pa), combined with an existing ...
Andreas H, Diacon +11 more
openaire +2 more sources
Evidence of safety for pretomanid and male reproductive health
The International Journal of Tuberculosis and Lung Disease, 2022Burke, A., Alffenaar, J., Denholm, J.
openaire +4 more sources
Pretomanid in the Treatment of Patients with Tuberculosis in the United States
New England Journal of Medicine, 2022Neela D. Goswami +2 more
openaire +2 more sources